Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal trial investigating docetaxel emulsion [ANX 514; Adventrx Pharmaceuticals] without corticosteriod premedication, compared with docetaxel [Taxotere; sanofi-aventis] with corticosteroid premedication, in patients with non-small cell lung cancer that has failed prior platinum-based therapy.

Next Previous
X
Search
Trial Profile

A pivotal trial investigating docetaxel emulsion [ANX 514; Adventrx Pharmaceuticals] without corticosteriod premedication, compared with docetaxel [Taxotere; sanofi-aventis] with corticosteroid premedication, in patients with non-small cell lung cancer that has failed prior platinum-based therapy.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2011

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational

    • Most Recent Events

    • 27 Oct 2011 ADVENTRX and the US FDA have met to discuss the trial, and agree that it will provide sufficient clinical data to support approval of the docetaxel emulsion (ANX 514), according to an ADVENTRX media release. The company expects to fline and NDA in 2014.
    • 03 Oct 2011 Planned initiation date changed to 1 Jan 2012, according to an ADVENTRX Pharmaceuticals media release.
    • 28 Mar 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top